Related Experiment Video

Updated: Jan 25, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K

Ivabradine for treatment of heart failure

Edimar Alcides Bocchi1, Vera Maria Cury Salemi1

  • 1a Heart Failure Team , Heart Institute (Incor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo , São Paulo , Brazil.

Expert Opinion on Drug Safety
|May 11, 2019
PubMed

Insights

Ivabradine effectively reduces heart rate in heart failure with reduced ejection fraction (HFrEF), improving patient outcomes. This heart rate-lowering medication is recommended by major guidelines for HFrEF management.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure with reduced ejection fraction (HFrEF) is linked to poorer prognosis.
  • Elevated heart rate (HR) is a significant predictor of adverse outcomes in HFrEF patients.

Purpose of the Study:

  • To review the effects of ivabradine on heart failure (HF) outcomes.
  • To assess the safety and efficacy of ivabradine in various HF populations.

Main Methods:

  • Review of published data, including the SHIFT trial and CONSTATHE-DHF study.
  • Analysis of ivabradine's impact on heart rate, cardiac function, and clinical outcomes.

Main Results:

  • Ivabradine improves chronic HFrEF outcomes and shows promise in acute decompensated HF (ADHF).
  • Ivabradine reduced HR and improved cardiac function in ADHF patients.
  • Ivabradine demonstrated benefits in pediatric HFrEF and showed a trend toward reduced mortality in chagasic patients.

Conclusions:

  • Ivabradine is a safe and cost-effective treatment option for HFrEF, supported by major clinical guidelines.
  • Ivabradine offers a promising therapeutic strategy for both chronic and acute HF management.
Abstract

Keywords:
Chagas diseaseHeart failurecost-effectivenessdecompensated heart failure chronic heart failureheart rateivabradineprognosis

More Related Videos

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.4K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
812
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.1K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
751
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
289
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
846
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
239